Lung adenocarcinoma cells floating in lymphatic vessels resist anoikis by expressing phosphorylated Src

Journal of Pathology

Volumn 220, Issue 5, 2010, Pages 574-585

  Sakuma, Yuji ^a   Takeuchi, Tomoyo ^a,b   Nakamura, Yoshiyasu ^a   Yoshihara, Mitsuyo ^a   Matsukuma, Shoichi ^a   Nakayama, Haruhiko ^a   Ohgane, Naoki ^a   Yokose, Tomoyuki ^a   Kameda, Yoichi ^a   Tsuchiya, Eiju ^a   Miyagi, Yohei ^a  

^a KANAGAWA CANCER CENTER   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Anoikis resistance; E cadherin; Epithelial mesenchymal transition (EMT); Lung adenocarcinoma; Src

Indexed keywords

ABELSON KINASE; BOSUTINIB; IMATINIB; PROTEIN TYROSINE KINASE; STEM CELL FACTOR; UVOMORULIN;

ADULT; AGED; ANOIKIS; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LYMPH VESSEL; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPHEROID CELL;

ADENOCARCINOMA; ADULT; AGED; ANILINE COMPOUNDS; ANOIKIS; ANTINEOPLASTIC AGENTS; CADHERINS; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC VESSELS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASTIC CELLS, CIRCULATING; NITRILES; ONCOGENE PROTEINS V-ABL; PHOSPHORYLATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRAZOLES; PYRIMIDINES; QUINOLINES; SPHEROIDS, CELLULAR; SRC-FAMILY KINASES; TUMOR CELLS, CULTURED;

EID: 77949863504     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2676     Document Type: Article

References (39)

1. Note: Reference 39 is cited in the Supporting information to this article. 1. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994;124:619-626.
2. Simpson CD, Anyiwe K, Schimmer AD. Anoikis resistance and tumor metastasis. Cancer Lett 2008;272:177-185.
3. Sakuma Y, Okamoto N, Saito H, Yamada K, Yokose T, Kiyoshima M, et al. A logistic regression predictive model and the outcome of patients with resected lung adenocarcinoma of 2 cm or less in size. Lung Cancer 2009;65:85-90.
4. Windham TC, Parikh NU, Siwak DR, Summy JM, McConkey DJ, Kraker AJ, et al. Src activation regulates anoikis in human colon tumor cell lines. Oncogene 2002;21:7797-7807.
5. Wei L, Yang Y, Zhang X, Yu Q. Altered regulation of Src upon cell detachment protects human lung adenocarcinoma cells from anoikis. Oncogene 2004;23:9052-9061.
6. Woods NT, Yamaguchi H, Lee FY, Bhalla KN, Wang HG. Anoikis, initiated by Mcl-1 degradation and Bim induction, is deregulated during oncogenesis. Cancer Res 2007;67:10744-10752.
7. Giaccone G, Zucali PA. Src as a potential therapeutic target in non-small-cell lung cancer. Ann Oncol 2008;19:1219-1223.
8. Masaki T, Igarashi K, Tokuda M, Yukimasa S, Han F, Jin YJ, et al. pp60c-src activation in lung adenocarcinoma. Eur J Cancer 2003;39:1447-1455.
9. Zhang J, Kalyankrishna S, Wislez M, Thilaganathan N, Saigal B, Wei W, et al. SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol 2007;170:366-376.
10. Song L, Morris M, Bagui T, Lee FY, Jove R, Haura EB. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 2006;66:5542-5548.
11. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nature Rev Cancer 2007;7:169- 181.
12. Bromann PA, Korkaya H, Courtneidge SA. The interplay between Src family kinases and receptor tyrosine kinases. Oncogene 2004;23:7957-7968.
13. Uekita T, Jia L, Narisawa-Saito M, Yokota J, Kiyono T, Sakai R. CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma. Mol Cell Biol 2007;27:7649-7660.
14. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nature Rev Cancer 2002;2:442-454.
15. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-1481.
16. Mansy SS. Agarose cell block: innovated technique for the processing of urine cytology for electron microscopy examination. Ultrastruct Pathol 2004;28:15-21.
17. Matsukuma S, Yoshihara M, Kasai F, Kato A, Yoshida A, Akaike M, et al. Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay. J Mol Diagn 2006;8:504-512.
18. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A 2007;104:19936-19941.
19. Gong Y, Somwar R, Politi K, Balak M, Chmielecki J, Jiang X, et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med 2007;4:e294.
20. Deng J, Shimamura T, Perera S, Carlson NE, Cai D, Shapiro GI, et al. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res 2007;67:11867-11875.
21. Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 2007;4:1681- 1689.
22. Cragg MS, Jansen ES, Cook M, Harris C, Strasser A, Scott CL. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest 2008;118:3651-3659.
23. Tatton L, Morley GM, Chopra R, Khwaja A. The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases. J Biol Chem 2003;278:4847-4853.
24. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nature Rev Cancer 2007;7:345-356.
25. Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J, et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003;63:375-381.
26. Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M, et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009;27:469-471.
27. Green SK, Francia G, Isidoro C, Kerbel RS. Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro. Mol Cancer Ther 2004;3:149-159.
28. Pickl M, Ries CH. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 2009;28:461-468.
29. Yamaguchi H, Woods NT, Dorsey JF, Takahashi Y, Gjertsen NR, Yeatman T, et al. SRC directly phosphorylates Bif-1 and prevents its interaction with Bax and the initiation of anoikis. J Biol Chem 2008;283: 19112-19118.
30. Desgrosellier JS, Barnes LA, Shields DJ, Huang M, Lau SK, Prévost N, et al. An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nature Med 2009;15:1163-1169.
31. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 2008;68:3645-3654.
32. Cowley GP, Smith ME. Modulation of E-cadherin expression and morphological phenotype in the intravascular component of adenocarcinomas. Int J Cancer 1995;60:325-329.
33. Tomlinson JS, Alpaugh ML, Barsky SH. An intact overexpressed E-cadherin/alpha,beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res 2001;61:5231-5241.
34. Kleer CG, van Golen KL, Braun T, Merajver SD. Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol 2001;14:458- 464.
35. Shen X, Kramer RH. Adhesion-mediated squamous cell carcinoma survival through ligand-independent activation of epidermal growth factor receptor. Am J Pathol 2004;165:1315-1329.
36. Mueller S, Cadenas E, Schönthal AH. p21WAF1 regulates anchorage-independent growth of HCT116 colon carcinoma cells via E-cadherin expression. Cancer Res 2000;60:156-163.
37. Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY, et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 2009;461:109-113.
38. Giannoni E, Fiaschi T, Ramponi G, Chiarugi P. Redox regulation of anoikis resistance of metastatic prostate cancer cells: key role for Src and EGFR-mediated pro-survival signals. Oncogene 2009;28:2074-2086.
39. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. IARC: Lyon, 2004; 10-44.